Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy
N. Morikawa et al., Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy, BIOL PHAR B, 23(6), 2000, pp. 784-787
This report investigates the pharmacokinetics of cytosine arabinoside (Ara-
C), methotrexate (MTX), nimustine (ACNU) and valproic acid (VPA) in cerebro
spinal fluid (CSF) during CSF perfusion chemotherapy. Japanese woman with d
isseminated glioblastoma was, on admission, on a stable oral regimen of pro
longed-release VPA tablets (Depakene(TM)-R), 400 mg twice a day, for seizur
e control. Twelve courses of CSF perfusion chemotherapy with Ara-C, MTX, an
d ACNU were administered. Plasma samples and CSF samples via Ommaya reservo
irs were obtained during the eleventh course of treatment. The Ara-C and AC
RTU concentrations were measured by HPLC. The MTX and VPA concentrations we
re measured by fluorescence polarization immunoassay.
During CSF perfusion themotherapy, the highest CSF concentrations of Ara-C,
MTX, and ACNU were observed at the end of the perfusion and decreased in a
monoexponential pattern. The half-lives of Ara-C, MTX, and ACNU were 2.65,
3.52, and 0.71h, respectively. No anticancer drugs were detectable in plas
ma during CSF perfusion chemotherapy. Before CSF perfusion chemotherapy; th
e free VPA concentration in plasma was 14.4% of the total VPA concentration
. The mean total and fi ee VPA concentrations in plasma were 78.0 +/- 0.8 a
nd 10.9 +/- 0.3 mu g/ml, respectively. The free VPA concentrations in plasm
a and in CSF were of similar values. At the end of perfusion, the lowest fr
ee VPA concentration in CSF was 30.3% of that at the initiation of perfusio
n. The free VPA concentrations in CSF at 3, 7, 23, and 47 h after the end o
f perfusion were 79.8, 93.5, 100.9, and 100.9% respectively of that at the
initiation of perfusion. During CSF perfusion chemotherapy, the ratio of fr
ee VPA concentrations to the total VPA in CSF was 86.3 +/- 6.9%. The VPA co
ncentrations in CSF rapidly decreased during the CSF perfusion but recovere
d to pre-treatment levels within 7 h.